Abbott Reports Third-Quarter 2025 Results and Reaffirms Full-Year Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Make sure you own this high-quality MedTech stock: RBC
October 17, 2025 4:00 PM EDTRBC Capital Markets reiterated its Outperform rating on one well-known MedTech stock in a note this week, calling it a high-quality company and saying it would be buyers following what it described as a quarter marked by transient headwinds.
The firm said Abbott's (NYSE: ABT) underlying business momentum is intact, even as the... More
Abbott (ABT) Reports In-Line Q3 EPS, Misses on Revenue; Offers FY25 EPS Guidance
October 15, 2025 7:32 AM EDTAbbott (NYSE: ABT) reported Q3 EPS of $1.30, in-line with the analyst estimate of $1.30. Revenue for the quarter came in at $11.37 billion versus the consensus estimate of $11.4 billion.
GUIDANCE:
Abbott sees FY2025 EPS of $5.12-$5.18, versus the consensus of $5.14.
For earnings history and earnings-related data on Abbott (ABT) click here.
... More